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during 2012–2014 in Karachi, Pakistan
Kauser Jabeen1*, Pushpa Bhawan Mal1, Erum Khan1, Saeeda Chandio1, Susanne Jacobsson2 and Magnus Unemo2
Abstract
Background: Globally, increasing antimicrobial resistance (AMR) in Neisseria gonorrhoea has led to decreased
treatment options for gonorrhoea. Continuous monitoring of resistance is crucial to determine evolving resistance
trends in Neisseria gonorrhoea and to suggest treatment recommendations. Quality assured gonococcal AMR data
from Pakistan are mainly lacking. This study was performed to determine prevalence and trends of gonococcal AMR
and molecular epidemiology of local strains during 2012–2014 in Karachi, Pakistan.
Methods: Gonococcal isolates (n = 100) were obtained from urogenital specimens submitted to the Aga Khan University
Laboratory, Karachi, Pakistan. Antimicrobial susceptibility was determined using Etest and molecular epidemiology was
assessed by N. gonorrhoeae multiantigen sequence typing (NG-MAST). Quality control was performed using
N. gonorrhoeae WHO reference strains C, F, G, K, L, M, N, O, and P, and ATCC 49226.
Results: Susceptibility to spectinomycin, ceftriaxone and cefixime was 100 % and to azithromycin was 99 %. All isolates
had low ceftriaxone MICs, i.e., ≤0.032 mg/L. Resistance to ciprofloxacin, tetracycline and penicillin G were 86 %, 51 % and
43 %, respectively. NG-MAST analysis identified 74 different sequence types (STs).
Conclusions: A highly diversified gonococcal population, 74 NG-MAST STs (62 novel STs) with an increased resistance to
penicillin G, ciprofloxacin and tetracycline circulated in Karachi, Pakistan. Fortunately, no resistance to ceftriaxone was
detected. Accordingly, ceftriaxone can continuously be recommended as the treatment of choice. However it is
recommended to increase the dose of ceftriaxone from 125 mg intramuscularly to 250 mg intramuscularly due to
ceftriaxone MIC creep and emerging resistance reported in the region. Furthermore, due to the high level of
resistance to ciprofloxacin (86 %) it is essential to exclude ciprofloxacin from the recommended first-line therapy.
It is imperative to significantly broaden the gonococcal AMR monitoring with participation from other laboratories and
cities in Pakistan.
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Background
Global Neisseria gonorrhoeae incidence among adults is
78 million of the estimated 357 million cases of new
sexually transmitted infections (STIs). Gonorrhoea is
one of the most commonly reported STI with 111 cases
per 100,000 population in the United States of America in
2014 [1–3]. Unfortunately, due to the lack of appropriate
etiological diagnosis of gonorrhoea in many settings of
Pakistan, no reliable figures regarding the incidence of
gonococcal infections nationally exist.
N. gonorrhoeae was recently assigned as a “superbug”
due to its ability to develop and retain in vitro and clin-
ical resistance, i.e. resulting in treatment failures, to all
antimicrobial agents available for treatment of gonor-
rhoea [2, 4–7]. The evolving resistance to ceftriaxone,
the last treatment option for empirical therapy of gonor-
rhoeae has resulted in a fear of an era with extremely diffi-
cult to cure or possibly untreatable gonorrhoea [5–7]. Due
to this emergent public health concern, the World Health
Organization (WHO) in 2012 recommended a global
action plan to halt the progression of N. gonorrhoeae anti-
microbial resistance (AMR). This action plan strongly
emphasizes the need of significantly enhanced surveillance
of gonococcal AMR, using quality assured methods to
monitor resistance trends, identify any emerging resist-
ance and inform revisions of evidence-based treatment
guidelines. The WHO has also suggested strong liaisons
with other regional and national GASPs by re-launching
the WHO Global Gonococcal Antimicrobial Surveillance
Program (GASP) [7].
Despite these recommendations, surveillance of AMR
in N. gonorrhoeae is difficult in settings where no na-
tional or regional GASP has been initiated. Inadequacy
or complete absence of appropriate GASPs has been
recently highlighted in Latin America, the Caribbean,
Eastern Europe, Central Asia and Africa [2, 7–9]. This is
certainly true also for the WHO Eastern Mediterranean
Region (EMR). The WHO EMR includes the highly pop-
ulated Pakistan with 182 million inhabitants, where no
programme-based surveillance of gonococcal infections
or AMR exists. In Pakistan, inadequate capacity to de-
tect N. gonorrhoeae and perform quality assured AMR
testing of N. gonorrhoeae in many laboratories are major
factors that contribute to the absence of any national
gonococcal AMR data. In small research studies, an
increasing resistance to ciprofloxacin, penicillin and
tetracycline in N. gonorrhoeae has been reported, but no
resistance to extended-spectrum cephalosporins (ESCs)
has yet been identified in Pakistan [10, 11]. However, in
these studies very limited numbers of N. gonorrhoeae
isolates were examined, and in general mainly qualitative
disc diffusion methods have been used for AMR testing
rather than the more reliable and quality assured quanti-
tative methods, agar dilution and Etest, measuring the
minimum inhibitory concentrations (MICs) of antimi-
crobials. In Pakistan, ceftriaxone 125 mg intramuscularly
(IM) single dose (mostly used), cefixime 400 mg oral
single dose or ciprofloxacin 500 mg oral single dose are
currently the recommended first-line for empirical therapy
of gonorrhoea. Alternative treatment option is azithromy-
cin, 1 g oral single dose [12]. However, additional less ef-
fective antimicrobials such as penicillins and tetracyclines
can also be used in both the private and public sector, and
antimicrobials are freely available “over-the-counter” with-
out prescriptions.
In addition to gonococcal AMR surveillance, under-
standing of the transmission of different gonococcal
strains in the population is critical for effective control
of gonorrhoea. N. gonorrhoeae multiantigen sequence
typing (NG-MAST) [13] has been used globally to study
prevalent strain genotypes, their transmission in sexual
networks and core groups, and to describe distributions
of AMR strains [14]. Although gonococcal prevalence
surveys from Pakistan have reported rates ranging from
4.7 % to 20.2 % in high risk sex workers that suggest a
high transmission in core groups, no molecular epi-
demiological data on high number of strains using NG-
MAST is available [15]. A recent study evaluating AMR
and genetic characteristics of gonococcal strains from
Pakistan, India and Bhutan reported a highly diversified
strain population [16]. However, this study included a low
number (n = 18) of gonococcal isolates from Pakistan and
recommended the need for expanded and ongoing sur-
veillance with large number of gonococcal isolates in
Pakistan.
The present study evaluated the prevalence and trends
of N. gonorrhoeae AMR and described the genotypic
distribution, using NG-MAST, of N. gonorrhoeae isolates
cultured in 2012–2014 in Karachi, Pakistan.
Methods
Biological samples
The present research was conducted at the Aga Khan Uni-
versity (AKU) laboratories based in Karachi, Pakistan. The
AKU laboratories comprise the largest laboratory network
in Pakistan with satellite units in major cities and towns.
The AKU Laboratory in Karachi was included as a sentinel
site in the WHO GASP in 2012. Since then the laboratory
regularly participates in the external quality assessment
schemes of the WHO GASP with excellent result. In the
current research, 100 mainly consecutive N. gonorrhoeae
isolates cultured from urethral swabs (n = 85), high vaginal
and cervical swabs (n = 14) and conjunctival swab (n = 1)
as part of routine clinical care from January 2012 to
February 2014 were included. N. gonorrhoeae isolates were
identified by colony morphology, Gram staining, oxi-
dase test, sugar utilization and Remel RapidNH® Panel
(BioMerieux, France). These N. gonorrhoeae isolates
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have also been used in a study evaluating two different
disc diffusion methods for susceptibility testing of N.
gonorrhoeae (BMC Microbiology, accepted). All isolates
were preserved in sterile 10 % glycerol phosphate broth
at −70 °C and subsequently shipped with professional
courier service (World Courier) on dry ice to Örebro
University Hospital, Örebro, Sweden for the NG-MAST
analysis. All cultures were performed according to stand-
ard protocol as part of the routine diagnostics and did not
include patients’ identification. The study was approved
by the Ethical Review Committee of Aga Khan University
(Exemption #4052-Pat-ERC-16), and did not require in-
formed consent as samples were taken as part of routine
clinical care.
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing was done at the Micro-
biology laboratory of the Aga Khan University, Karachi,
Pakistan. The MICs (mg/L) of ceftriaxone, cefixime, peni-
cillin G, spectinomycin, ciprofloxacin, azithromycin and
tetracycline were determined by the Etest (BioMerieux AB,
Solna, Sweden) on GC agar base (Difco GC agar base
medium, Becton, Dickinson, Sparks, MD, USA) with 1 %
BBL IsoVitalex Enrichment (Becton, Dickinson, Sparks,
MD, USA), according to the instructions from the manu-
facturer. MICs were interpreted using breakpoints for
resistance, intermediate susceptibility and susceptibility
according to the Clinical and Laboratory Standards Insti-
tute (CLSI) [17]. For azithromycin, breakpoints are not
available as per CLSI, accordingly, the MIC breakpoints
from the European Committee on Antimicrobial Suscepti-
bility Testing (EUCAST; www.eucast.org) were applied.
For quality controls, as recommended by the CLSI the N.
gonorrhoeae reference strain ATCC 49226 was included in
each testing. In addition, the N. gonorrhoeae WHO N.
gonorrhoeae reference strains C, F, G, K, L, M, N, O, and P
[18] were used as quality controls. β-lactamase production
was identified by a chromogenic cephalosporin method
using nitrocefin reagent (Oxoid, Hampshire, UK).
Molecular epidemiological typing (NG-MAST)
Genomic DNA was isolated from cultured gonococcal
isolates using the NorDiag Bullet robot (NorDiag ASA
Company, Oslo, Norway) with BUGS’n BEADS STI-
fast kit (NorDiag ASA Company, Oslo, Norway), ac-
cording to the manufacturer’s instructions. NG-MAST
[13] was performed as previously described [19]. NG-
MAST allele numbers of the more variable segments of
porB and tbpB, and sequence types (STs) were evalu-
ated using the NG-MAST website (www.ng-mast.net).
NG-MAST genogroups, comprising the main ST plus
genetically associated STs, were assigned as reported in
past studies. Briefly, a genogroup was defined as all
STs which shared one allele and exhibited >99 %
homogeneity in the other allele (≤5 bp difference for
porB and ≤4 bp for tbpB) [20].
Result
Patient characteristics
N. gonorrhoeae isolates were grown from 86 (86 %) males
and 14 (14 %) females. The mean age for the males was
30 years (median age: 29 years; range: 1.3 to 55 years) and
for the females 29 years (median age: 29 years; range: 5 to
47 years).
Antimicrobial susceptibility of N. gonorrhoeae isolates in
2012–2014 (n = 100) in Karachi, Pakistan
Summary of result of antimicrobial susceptibilities are
given in Table 1.
During 2012–2014, all (100 %) isolates were suscep-
tible to ceftriaxone, cefixime and spectinomycin, and
99 % susceptible to azithromycin, that is, only one iso-
late was resistant to azithromycin (MIC = 4 mg/L). Fur-
thermore, all isolates had MICs < 0.016 mg/L and MICs
≤0.032 mg/L of cefixime and ceftriaxone, respectively.
However, the pattern of resistance the levels of resist-
ance to ciprofloxacin, tetracycline and penicillin G were
high that is, 86 %, 51 % and 43 %, respectively (Table 1).
The resistance to ciprofloxacin (75–100 %), tetracycline
(42–50 %) and penicillin G (25–42 %) during 2012–2014
remained high. Nevertheless, the resistance to penicillin G
decreased from 42 % to 25 %, which was due to the de-
crease of β-lactamase producing isolates in 2014 (Table 2).
Neisseria gonorrhoeae multiantigen sequence typing
(NG-MAST)
In total, 94 (94 %) isolates could be successfully typed
with NG-MAST. Remaining six (6 %) isolates were not
revived due to contamination. Seventy-four different STs
were identified and 62 STs (83.8 %) of these had not
been previously described. The most prevalent STs were
ST338 (n = 3 isolates), ST3328 (n = 3), ST10876 (n = 3),
and ST10886 (n = 3). Twelve STs were represented by
two isolates and 58 STs were represented by single iso-
lates. In total, 36 porB alleles and 32 tbpB alleles were
found. The most common porB alleles and tbpB alleles
were porB1173 (12 isolates), porB90 (n = 11), porB251
(n = 11), tbpB136 (n = 12) and tbpB121 (n = 10). ST338,
ST3328 and ST10878 could be grouped in to the gen-
ogroup G338 (n = 8).
In Additional file 1: Table S1, the AMR of isolates
assigned as the more prevalent NG-MAST STs is de-
scribed. Out of the 74 identified STs, 33 (44 %) STs in-
cluded N. gonorrhoeae isolates (n = 36) showing resistance
to penicillin G, 43 (57 %) STs having resistance to tetra-
cycline (n = 44), and 61 (81 %) STs displaying resistance to
ciprofloxacin (n = 73). The only azithromycin resistant
isolate (MIC = 4 mg/L) was assigned as ST8580.
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Discussion
This study showed that the susceptibility to ceftriaxone
(100 %), cefixime (100 %), spectinomycin (100 %) and
azithromycin (99 %) has remained high in Karachi,
Pakistan. Accordingly, the results of the current study sup-
port using ceftriaxone as empiric treatment of choice in
Pakistan for gonorrhoea, which has been recommended
since year 2010 [12]. However, due to the increasing MICs
of ceftriaxone and the emerging ceftriaxone resistance
internationally the dose in Pakistan is recommended to be
increased from 125 mg IM to at least 250 mg IM. Further-
more, because of increased resistance to ciprofloxacin
(86 %) in Karachi it is important to exclude ciprofloxacin
from the recommended first-line therapies. The reasons
for the retained high susceptibility to ceftriaxone in
Pakistan are unknown. This showed that gonococcal strain
with decreased susceptibility to ESCs has neither been
imported or if imported has not been successful to retain
and establish local spread. However, it might also reflect
that the ESCs resistance selection pressure has been low
in gonococcal infections because ceftriaxone for therapy
has only been recommended since 2010 (and instead
ciprofloxacin was frequently used). In cases of ceftriaxone
resistance, unavailability of ceftriaxone or severe β-lactam
allergy, spectinomycin can be used as the second-line
treatment. Azithromycin 2 g, should be added to the spec-
tinomycin regimen in case of pharyngeal gonorrhoea, in
accordance to European gonorrhea treatment guideline
[21]. In current study, only one (1 %) azithromycin resist-
ant isolate (ST8580) was found. Consequently, azithromy-
cin remains effective against N. gonorrhoeae in Pakistan.
However, due to the risk of selecting resistance (including
high-level resistance) to azithromycin in N. gonorrhoeae
[5], as well as in etiological agents of other sexually trans-
mitted infections, this antimicrobial should mainly not be
used in gonorrhoea monotherapy and, if it has to be used
(e.g., due to severe β-lactam allergy or resistance or
unavailability of ceftriaxone and spectinomycin), azithro-
mycin 2 g single oral dose should be used. Instead, it is
recommended in the US [22] and European [21] gonor-
rhoea treatment guidelines that azithromycin should be
added to ceftriaxone in the recommended first-line
regimen. These dual antimicrobial therapies can be rec-
ommended in settings where ceftriaxone resistance has
been verified or has not been excluded. Combined anti-
microbial therapy will not only successfully eliminate
gonorrhoea but also Chlamydia trachomatis infections
and many M. genitalium infections. High levels of resist-
ance to ciprofloxacin (86 %), tetracycline (51 %) and peni-
cillin G (43 %) were identified in Karachi, Pakistan.
Because of increased resistance to these antibiotics locally
and also in most other countries worldwide, none of them
ought to be suggested for empirical therapy of choice of
gonorrhea in Pakistan or internationally [2, 5, 8–11].
Worryingly, in Pakistan penicillins, tetracyclines, fluoro-
quinolones, and macrolides are still commonly used as
treatment options for gonorrhoea and these antibiotics are
easily accessible “over-the-counter”. Due to this practice, it
is crucial to substantially enhance the continuous moni-
toring of gonococcal AMR with a focus on emergence of
resistance to ceftriaxone, spectinomycin and azithromycin,
using MIC determination and also monitor treatment fail-
ures and gonococcal molecular epidemiological character-
istics in Pakistan. It is therefore recommended to evaluate
AMR annually with representation from more cities or
Table 1 Antimicrobial susceptibility of Neisseria gonorrhoeae isolates (n = 100) in Karachi, Pakistan, 2012–2014
Antimicrobial MIC range (mg/L) MIC50 (mg/L) MIC90 (mg/L) S (%) I (%) R (%)
Ceftriaxone 0.002–0.032 0.008 0.016 100 0 0
Cefixime <0.016 <0.016 <0.016 100 0 0
Spectinomycin 0.25–16 4 8 100 0 0
Azithromycin 0.016–4 0.094 0.25 99 - 1
Penicillin G 0.004–32 0.5 12 8 49 43
Tetracycline 0.12–96 3 24 12 37 51
Ciprofloxacin 0.25–32 4 14 0 14 86
MIC Minimum inhibitory concentration of an antibiotic necessary to inhibit the growth of a target organism, MIC90 Minimum inhibitory concentration of an
antibiotic at which 90 % of the isolates were inhibited, MIC50 Minimum inhibitory concentration of an antibiotic at which 50 % of the isolates were inhibited, S
Susceptibility; I Intermediate susceptibility, R Resistance
Table 2 Percentage (%) of antimicrobial resistance and β-
lactamase production in Neisseria gonorrhoeae isolates (n = 100)
obtained in Karachi, Pakistan, separated in 2012, 2013 and 2014
Antimicrobial 2012 (n = 48) 2013 (n = 40) 2014 (n = 12)
Ceftriaxone 0 0 0
Cefixime 0 0 0
Spectinomycin 0 0 0
Azithromycin 2 0 0
Penicillin G 42 42 25
Tetracycline 50 45 42
Ciprofloxacin 75 88 100
β-lactamase production 42 40 25
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regions to generate national data. It is also imperative to
associate AMR to epidemiological data for development of
effective control and prevention strategies. Consequently,
financial assurance or support, both national and inter-
national, is crucial to emphasize continuous monitoring.
The political commitment of the country leadership to
curtail AMR in Pakistan and other countries in the WHO
EMR will also be required.
NG-MAST has been used as a standard technique to
evaluate clonal spread of gonococcal strains within high
risk populations and to relate therapeutic failure with dis-
semination of particular strain types [14]. In the present
study, 74 different NG-MAST STs among 94 isolates were
identified. The high number of STs represented by only
one isolate (n = 58) and STs that have not been previously
described (62 novel STs) make the results hard to value.
These results may be associated with the large catchment
area, poor diagnostic capabilities in laboratories, lack sex-
ual contacts tracing, and evolution of STs in Pakistan.
Nevertheless, some NG-MAST ST clusters identified, e.g.
G338 (n = 8), were associated with resistance to all three
of the previously used antimicrobials ciprofloxacin, peni-
cillin G and tetracycline. The successful ST1407 clone or
genetically closely related STs belonging to genogroup
1407 associated with cefixime and ceftriaxone treatment
failure internationally [5, 6], were not found in the present
study.
The present study was performed on small number of
strains which were collected as per physicians request
and the researchers had no main control over patient
selection. Therefore the results could not be generalized
to the entire population. Additionally clinical data was
not available from the patients to evaluate risk factors
and treatment response. Despite these limitations, the
results of this study are exceedingly important and will
provide a baseline for future studies.
Conclusions
A highly diversified gonococcal population, 74 NG-MAST
STs (n = 62 novel STs) identified, with a high resistance to
ciprofloxacin, penicillin G and tetracycline circulated in
Karachi, Pakistan. Fortunately, no resistance to ceftriax-
one was detected and ceftriaxone can continuously be
recommended as the drug of choice. However it is rec-
ommended to increase the dose of ceftriaxone from
125 mg intramuscularly to 250 mg intramuscularly due
to ceftriaxone MIC creep and emerging resistance re-
ported in the region. Furthermore, due to the high re-
sistance to ciprofloxacin (86 %) in Karachi it is essential
to exclude ciprofloxacin from the recommended first-
line therapies. It is important to emphasize the continu-
ous monitoring of gonococcal AMR and investigate
therapeutic failure in patients from other regions of
Pakistan.
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